Abstract: With the deepening understanding of the pathophysiology of heart failure (HF),an increasing number of therapeutic drugs for HF have been developed.The new drug empagliflozin has been approved and widely used in the treatment of HF in human medicine.However,the development of HF treatment drugs for dogs and cats has been relatively slow.The available drug options are limited,with a single mechanism of action,and lack sufficient safety and efficacy data.Accelerating the research and development of novel HF treatment drugs for dogs and cats is crucial for the management and treatment of HF in these animals.In this study,key words such as "heart failure","therapy","medicine","dogs","canine","cats","feline" were used to search databases including PubMed,Google Scholar,Web of Science,Baidu Scholar,CNKI,and so on.The review of results indicates that the current focus of HF drug development is on inhibiting or directly reversing ventricular remodeling,including drugs that act directly on the heart or on the peripheral circulation.Recent studies have shown that sodium-glucose cotransporter 2 inhibitors (SGLT2i),angiotensin receptor-neprilysin inhibitors (ARNi),mineralocorticoid receptor antagonists (MRA),soluble guanylate cyclase (sGC) stimulators,and cardiac myosin activators are five categories of drugs with potential for HF treatment.These drugs have unique mechanisms of action,and animal experiments or human clinical trial results have demonstrated their significant improvement in cardiac contractile function,prevention or reduction of harmful neurohormonal activation and ventricular remodeling.They hold promise as novel frontline drugs for the treatment of heart failure in dogs and cats.This article summarized the research progress on the mechanisms of action,efficacy,and safety of these five categories of drugs,aiming to provide insights for future research on HF drugs in dogs and cats.

Key words: dog; cat; heart failure; ventricular remodeling; drug treatment